Stefan Ryser
Chief Executive Officer presso Trellis Bioscience, Inc.
Profilo
Dr. Stefan Ryser is Chief Executive Officer & Director at A-CUBE, Inc. He is on the Board of Directors at A-CUBE, Inc.
Dr. Ryser was previously employed as Founding Partner by Bear Stearns Health Innoventures Management LLC, a Director & Senior VP-Corporate Strategy by Telik, Inc., Chief Executive Officer by International Biomedicine Management Partners, Inc., Head-Research Staff by Hoffmann-La Roche, Inc., Chief of Staff-Research & Development by Roche & Genentech, Inc., a Managing Director by Bear Stearns Asset Management, Inc., and a Member by The European Association for Bioindustries.
He also served on the board at Tolerx, Inc., Achillion Pharmaceuticals, Inc., Arena Pharmaceuticals, Inc., Cytokinetics, Inc., Entelos, Inc., and Genaissance Pharmaceuticals, Inc.
He received his undergraduate degree from the University of Basel and a doctorate degree from the University of Basel.
Posizioni attive di Stefan Ryser
| Società | Posizione | Inizio |
|---|---|---|
Trellis Bioscience, Inc.
 Trellis Bioscience, Inc. BiotechnologyHealth Technology Trellis Bioscience, Inc. is discovers and develops novel human antibody therapeutics. It provides the discovery and development of therapeutic antibodies from human B cells. The firm develops the CellSpot antibody discovery platform, which enables the identification of antibodies directly from human blood. The company was founded by Lawrence Kauvar and Stote Ellsworth in 1998 and is headquartered in South San Francisco, CA. | Chief Executive Officer | - |
Precedenti posizioni note di Stefan Ryser
| Società | Posizione | Fine |
|---|---|---|
Telik, Inc.
 Telik, Inc. Pharmaceuticals: MajorHealth Technology Telik, Inc. is an innovative biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. Its TELINTRA product is used for treatment of cytopenias due to myelodysplastic syndrome and chemotherapy. The company's product candidates were discovered using its proprietary drug discovery technology TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Telik was founded in September 1988 and is headquartered in Palo Alto, CA. | Director/Board Member | 01/08/2009 |
Bear Stearns Health Innoventures Management LLC
 Bear Stearns Health Innoventures Management LLC Investment ManagersFinance A subsidiary of Bear Stearns Asset Management, Inc., Bear Stearns Health Innoventures Management LLC (BSHI) is a venture capital firm headquartered in New York City. | Chief Investment Officer | 31/03/2009 |
| ACHILLION PHARMACEUTICALS, INC. | Director/Board Member | 27/04/2007 |
| International Biomedicine Management Partners AG | Founder | 01/04/2000 |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Corporate Officer/Principal | 31/12/1997 |
Formazione di Stefan Ryser
| University of Basel | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| CYTOKINETICS, INCORPORATED | Health Technology |
| Aziende private | 14 |
|---|---|
Bear Stearns Asset Management, Inc.
 Bear Stearns Asset Management, Inc. Investment ManagersFinance Bear Stearns Asset Management Inc (Bear Stearns) is a Private Equity/Venture Capital firm, a subsidiary of The Bear Stearns Cos LLC founded in 1985. The firm is headquartered in the US. | Finance |
Telik, Inc.
Telik, Inc. Pharmaceuticals: MajorHealth Technology Telik, Inc. is an innovative biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. Its TELINTRA product is used for treatment of cytopenias due to myelodysplastic syndrome and chemotherapy. The company's product candidates were discovered using its proprietary drug discovery technology TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Telik was founded in September 1988 and is headquartered in Palo Alto, CA. | Health Technology |
Genaissance Pharmaceuticals, Inc.
 Genaissance Pharmaceuticals, Inc. BiotechnologyHealth Technology Genaissance Pharmaceuticals, Inc. develops and uses genetic information to diagnostic and therapeutic products. The company was founded by Kevin L. Rakin and Gualberto Ruano in 1992 and is headquartered in New Haven, CT. | Health Technology |
Arena Pharmaceuticals, Inc.
 Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protein-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in Park City, UT. | Health Technology |
Tolerx, Inc.
 Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Health Technology |
Trellis Bioscience, Inc.
Trellis Bioscience, Inc. BiotechnologyHealth Technology Trellis Bioscience, Inc. is discovers and develops novel human antibody therapeutics. It provides the discovery and development of therapeutic antibodies from human B cells. The firm develops the CellSpot antibody discovery platform, which enables the identification of antibodies directly from human blood. The company was founded by Lawrence Kauvar and Stote Ellsworth in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA. | Health Technology |
Entelos, Inc.
 Entelos, Inc. Information Technology ServicesTechnology Services Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA. | Technology Services |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
Bear Stearns Health Innoventures Management LLC
Bear Stearns Health Innoventures Management LLC Investment ManagersFinance A subsidiary of Bear Stearns Asset Management, Inc., Bear Stearns Health Innoventures Management LLC (BSHI) is a venture capital firm headquartered in New York City. | Finance |
| International Biomedicine Management Partners AG | Finance |
| The European Association for Bioindustries | |
| Roche & Genentech, Inc. | |
A-CUBE, Inc.
 A-CUBE, Inc. BiotechnologyHealth Technology A-CUBE, Inc. develops novel antibodies. It utilizes silico algorithms and to discover novel druggable targets suitable for developing human therapeutic interventions, including next generation drugs for commercially proven targets. The company was founded by Nobuyuki Ota is headquartered in Belmont, CA. | Health Technology |
- Borsa valori
- Insiders
- Stefan Ryser
